Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Zymeworks Inc. (ZYME)

Zymeworks completes Theravance Biopharma acquisition, issues $350 million secured notes

Neutral Impact 5 of 5 m&a Written later

Zymeworks completed its acquisition of Theravance Biopharma on September 23, 2026, and issued $350 million of senior secured notes to fund part of the cash consideration and contingent value rights payments. The filing also sets out contingent value rights (CVRs) that give holders a share of certain future license proceeds, a $50 million milestone payment and a share of net sales, with the filing stating that payment is uncertain.

Key points

  • Notes carry a fixed 8.25% interest rate and mature December 31, 2036, with quarterly interest payments beginning December 2026.
  • The notes are guaranteed by Zymeworks subsidiaries and secured by a first-priority lien on substantially all of the issuers' and guarantors' personal property, subject to customary exclusions.
  • CVR holders may receive 80% of net license proceeds within 10 years, a $50 million milestone payment on first commercial sale of ampreloxetine in specified markets, and 10% of net sales; the filing calls these payments highly speculative.
  • Zymeworks will hold a conference call on Monday, September 28, 2026, at 8:30 a.m. Eastern Time.

The filing

CompanyZymeworks Inc. (ZYME)
Form8-K, current report
Filed with the SECSep 23, 2026, 4:06 PM ET
Accession number0001193125-26-399383

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed2.03 New Direct Financial Obligation7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.